|
1
|
Ferlay J, Colombet M, Soerjomataram I,
Mathers C, Parkin DM, Piñeros M, Znaor A and Bray F: Estimating the
global cancer incidence and mortality in 2018: GLOBOCAN sources and
methods. Int J Cancer. 144:1941–1953. 2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Konno R, Konishi H, Sauvaget C, Ohashi Y
and Kakizoe T: Effectiveness of HPV vaccination against high grade
cervical lesions in Japan. Vaccine. 36:7913–7915. 2018.PubMed/NCBI View Article : Google Scholar
|
|
4
|
US Preventive Services Task Force. Curry
SJ, Krist AH, Owens DK, Barry MJ, Caughey AB, Davidson KW, Doubeni
CA, Epling JW Jr, Kemper AR, et al: Screening for cervical cancer:
US preventive services task force recommendation statement. JAMA.
320:674–686. 2018.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Ogilvie GS, van Niekerk D, Krajden M,
Smith LW, Cook D, Gondara L, Ceballos K, Quinlan D, Lee M, Martin
RE, et al: Effect of screening with primary cervical HPV testing vs
cytology testing on high-grade cervical intraepithelial neoplasia
at 48 months: The HPV FOCAL randomized clinical trial. JAMA.
320:43–52. 2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Ronco G, Giorgi-Rossi P, Carozzi F,
Confortini M, Dalla Palma P, Del Mistro A, Ghiringhello B, Girlando
S, Gillio-Tos A, De Marco L, et al: Efficacy of human
papillomavirus testing for the detection of invasive cervical
cancers and cervical intraepithelial neoplasia: A randomised
controlled trial. Lancet Oncol. 11:249–257. 2010.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Ronco G, Giorgi-Rossi P, Carozzi F, Dalla
Palma P, Del Mistro A, De Marco L, De Lillo M, Naldoni C, Pierotti
P, Rizzolo R, et al: Human papillomavirus testing and liquid-based
cytology in primary screening of women younger than 35 years:
Results at recruitment for a randomised controlled trial. Lancet
Oncol. 7:547–555. 2006.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Ronco G, Segnan N, Giorgi-Rossi P, Zappa
M, Casadei GP, Carozzi F, Dalla Palma P, Del Mistro A, Folicaldi S,
Gillio-Tos A, et al: Human papillomavirus testing and liquid-based
cytology: Results at recruitment from the new technologies for
cervical cancer randomized controlled trial. J Natl Cancer Inst.
98:765–774. 2006.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Ronco G, Giorgi-Rossi P, Carozzi F,
Confortini M, Dalla Palma P, Del Mistro A, Gillio-Tos A, Minucci D,
Naldoni C, Rizzolo R, et al: Results at recruitment from a
randomized controlled trial comparing human papillomavirus testing
alone with conventional cytology as the primary cervical cancer
screening test. J Natl Cancer Inst. 100:492–501. 2008.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Ogilvie GS, Krajden M, van Niekerk D,
Smith LW, Cook D, Ceballos K, Lee M, Gentile L, Gondara L,
Elwood-Martin R, et al: HPV for cervical cancer screening (HPV
FOCAL): Complete Round 1 results of a randomized trial comparing
HPV-based primary screening to liquid-based cytology for cervical
cancer. Int J Cancer. 140:440–448. 2017.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Leinonen MK, Nieminen P, Lönnberg S,
Malila N, Hakama M, Pokhrel A, Laurila P, Tarkkanen J and Anttila
A: Detection rates of precancerous and cancerous cervical lesions
within one screening round of primary human papillomavirus DNA
testing: Prospective randomised trial in Finland. BMJ.
345(e7789)2012.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Canfell K, Caruana M, Gebski V,
Darlington-Brown J, Heley S, Brotherton J, Gertig D, Jennett CJ,
Farnsworth A, Tan J, et al: Cervical screening with primary HPV
testing or cytology in a population of women in which those aged 33
years or younger had previously been offered HPV vaccination:
Results of the Compass pilot randomised trial. PLoS Med.
14(e1002388)2017.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Solomon D, Davey D, Kurman R, Moriarty A,
O'Connor D, Prey M, Raab S, Sherman M, Wilbur D, Wright T Jr, et
al: The 2001 Bethesda System: Terminology for reporting results of
cervical cytology. JAMA. 287:2114–2119. 2002.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Ki EY, Lee YK, Lee A and Park JS:
Comparison of the PANArray HPV genotyping chip test with the Cobas
4800 HPV and hybrid capture 2 tests for detection of HPV in ASCUS
women. Yonsei Med J. 59:662–668. 2018.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Sauvaget C, Nishino Y, Konno R, Tase T,
Morimoto T and Hisamichi S: Challenges in breast and cervical
cancer control in Japan. Lancet Oncol. 17:e305–e312.
2016.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Kurokawa T, Onuma T, Shinagawa A, Chino Y,
Kobayashi M and Yoshida Y: The ideal strategy for cervical cancer
screening in Japan: Result from the Fukui cervical cancer screening
study. Cytopathology. 29:361–367. 2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Tjalma W: HPV negative cervical cancers
and primary HPV screening. Facts Views Vis Obgyn. 10:107–113.
2018.PubMed/NCBI
|
|
18
|
Clifford GM, Smith JS, Aguado T and
Franceschi S: Comparison of HPV type distribution in high-grade
cervical lesions and cervical cancer: A meta-analysis. Br J Cancer.
89:101–105. 2003.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Guan P, Howell-Jones R, Li N, Bruni L, de
Sanjosé S, Franceschi S and Clifford GM: Human papillomavirus types
in 115,789 HPV-positive women: A meta-analysis from cervical
infection to cancer. Int J Cancer. 131:2349–2359. 2012.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Onuki M, Matsumoto K, Satoh T, Oki A,
Okada S, Minaguchi T, Ochi H, Nakao S, Someya K, Yamada N, et al:
Human papillomavirus infections among Japanese women: Age-related
prevalence and type-specific risk for cervical cancer. Cancer Sci.
100:1312–1316. 2009.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Kitchener HC, Almonte M, Wheeler P, Desai
M, Gilham C, Bailey A, Sargent A and Peto J: ARTISTIC Trial Study
Group: HPV testing in routine cervical screening: Cross sectional
data from the ARTISTIC trial. Br J Cancer. 95:56–61.
2006.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Kitchener HC, Gilham C, Sargent A, Bailey
A, Albrow R, Roberts C, Desai M, Mather J, Turner A, Moss S and
Peto J: A comparison of HPV DNA testing and liquid based cytology
over three rounds of primary cervical screening: Extended follow up
in the ARTISTIC trial. Eur J Cancer. 47:864–871. 2011.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Kitchener HC, Almonte M, Thomson C,
Wheeler P, Sargent A, Stoykova B, Gilham C, Baysson H, Roberts C,
Dowie R, et al: HPV testing in combination with liquid-based
cytology in primary cervical screening (ARTISTIC): A randomised
controlled trial. Lancet Oncol. 10:672–682. 2009.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Sargent A, Bailey A, Almonte M, Turner A,
Thomson C, Peto J, Desai M, Mather J, Moss S, Roberts C, et al:
Prevalence of type-specific HPV infection by age and grade of
cervical cytology: Data from the ARTISTIC trial. Br J Cancer.
98:1704–1709. 2008.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Castle PE, Stoler MH, Wright TC Jr, Sharma
A, Wright TL and Behrens CM: Performance of carcinogenic human
papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for
cervical cancer screening of women aged 25 years and older: A
subanalysis of the ATHENA study. Lancet Oncol. 12:880–890.
2011.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Cox JT, Castle PE, Behrens CM, Sharma A,
Wright TC Jr and Cuzick J: Athena HPV Study Group: Comparison of
cervical cancer screening strategies incorporating different
combinations of cytology, HPV testing, and genotyping for HPV
16/18: Results from the ATHENA HPV study. Am J Obstet Gynecol.
208:184.e1–184.e11. 2013.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Monsonego J, Cox JT, Behrens C, Sandri M,
Franco EL, Yap PS and Huh W: Prevalence of high-risk human
papilloma virus genotypes and associated risk of cervical
precancerous lesions in a large U.S. screening population: Data
from the ATHENA trial. Gynecol Oncol. 137:47–54. 2015.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Petry KU, Cox JT, Johnson K, Quint W,
Ridder R, Sideri M, Wright TC Jr and Behrens CM: Evaluating
HPV-negative CIN2+ in the ATHENA trial. Int J Cancer.
138:2932–2939. 2016.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Wright TC Jr, Stoler MH, Behrens CM, Apple
R, Derion T and Wright TL: The ATHENA human papillomavirus study:
Design, methods, and baseline results. Am J Obstet Gynecol.
206:46.e1–46.e11. 2012.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Wright TC Jr, Stoler MH, Sharma A, Zhang
G, Behrens C and Wright TL: ATHENA (Addressing THE Need for
Advanced HPV Diagnostics) Study Group: Evaluation of HPV-16 and
HPV-18 genotyping for the triage of women with high-risk HPV+
cytology-negative results. Am J Clin Pathol. 136:578–586.
2011.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Young RH and Clement PB: Endocervical
adenocarcinoma and its variants: Their morphology and differential
diagnosis. Histopathology. 41:185–207. 2002.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Schnatz PF, Guile M, O'Sullivan DM and
Sorosky JI: Clinical significance of atypical glandular cells on
cervical cytology. Obstet Gynecol. 107:701–708. 2006.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Lew JB, Simms KT, Smith MA, Hall M, Kang
YJ, Xu XM, Caruana M, Velentzis LS, Bessell T, Saville M, et al:
Primary HPV testing versus cytology-based cervical screening in
women in Australia vaccinated for HPV and unvaccinated:
Effectiveness and economic assessment for the national cervical
screening program. Lancet Public Health. 2:e96–e107.
2017.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Canfell K, Saville M, Caruana M, Gebski V,
Darlington-Brown J, Brotherton J, Heley S and Castle PE: Protocol
for Compass: A randomised controlled trial of primary HPV testing
versus cytology screening for cervical cancer in HPV-unvaccinated
and vaccinated women aged 25-69 years living in Australia. BMJ
Open. 8(e016700)2018.PubMed/NCBI View Article : Google Scholar
|
